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ObituaryGregory Robert Mundy
1942—2010On February 25, 2010, the bone and
mineral research community lost a super-
star. Greg Mundy, who succumbed to a
malignant brain tumor, held the John A.
Oates Chair in Translational Medicine at
Vanderbilt University, where he was re-
cruited in 2006 to develop its Center for
Bone Biology. He was also Professor of
Medicine, Pharmacology, Orthopedics,
and Cancer Biology.
Scientists are fortunate in that our most
direct competitors often become our
closest friends, and so it was with Greg
and me. We met in the late seventies,
when we were each chasing the ontogeny
of the osteoclast, whose hematological
origin was not yet established. We both
suspected the monocyte/macrophage
was central to the cell’s development
and competed ferociously to solve the
mystery. Amidst the competition, we dis-
covered we liked one another, and our
relationship evolved into a friendship that
went beyond science. We often visited
each other with our spouses and vaca-
tioned together. Greg, my competitor,
became one of my best friends.
There was a grace about Greg. He was
modest and had the capacity to make his
point inanonconfrontational,good-natured
manner. He considered teaching his most
important responsibility, and, as such,
trainees flocked to him. Greg mentored in
excess of 150 students and postdoctoral
fellows, many of whom now hold distin-
guished academic positions. At the same
time, his charisma and clarity of delivery
made him the most engaging of speakers
at conferences. Students and young inves-
tigators sought his company and advice.
Never disappointed, they were impressed
by his warmth and recollection of previous
chats regarding their research.
Greg grew up working on a peach farm
his family had carved out of the Australian
outback in the mid-19th century. The envi-
ronment was not conducive to higher
education, and sequential generations of
Mundys committed themselves to servicing
the land. When Greg’s parents became
aware of his academic potential, however,
they provided him with exceptional
schooling. He not only was an extraordinarystudentat secondaryschoolandMelbourne
University, where he received his Baccalau-
reate in Medicne and Surgery, but became
one of Australia’s most competitive cricket
players, twice winning the University’s
Cricket Club bowling average.
While his interests were broad, Greg’s
passion was to understand the mecha-
nisms of skeletal destruction in patients
with cancer. He did so by marrying the
disciplines of tumor and bone cell biology.
Greg’s interest in this issue harkened back
to the early seventies, while completing
his Doctor of Medicine degree at the
University of Tasmania. During his thesis
work on the cytogenetics of multiple
myeloma, he realized little was known
about the means by which this hematolog-
ical malignancy destroys bone, a question
he pursued the rest of his life. In 1972,
Greg, his wife Helen, and three small chil-
dren left Australia to join the laboratory of
Lawrence Raisz at the University of Ro-
chester. Larry had developed an organ
culture model to assay bone resorption
in vitro, and provided evidence that
marrow cells, particularly macrophages,
produce an osteoclast activating ‘‘factor’’
that Greg ultimately proved to be regu-
lated by prostaglandins. At the same
time, he discovered that the products of
osteoclastic bone resorption are chemo-
tactic to cancer cells, an observation thatCell Metabolislaid the foundation for the ‘‘viscous cycle
of tumor osteolysis,’’ the contribution for
whichGregwill likelybemost remembered.
This model holds that the skeletal lesions of
metastatic cancer, which reflect the activity
of tumor-recruited osteoclasts, ultimately
stimulate tumor growth and additional
bone destruction. This series of observa-
tions provided the rationale for treating
tumor osteolysis by antiosteoclastic drugs,
particularly bisphosphonates, whose
effectiveness Greg was first to demon-
strate in animal models. Consequently,
these agents are now standard therapy
in malignant skeletal disorders such as
myeloma and metastatic breast cancer.
In 1980, eight years after his appoint-
ment as Research Associate in the Raisz
Laboratory, Greg was recruited to serve
as Professor and Head of the Division of
Endocrinology and Metabolism at the
University of Texas Health Science Center,
San Antonio, where his major contribu-
tions came to fruition. Here he built one
of the world’s premier bone biology pro-
grams, ultimately holding the Heyser Chair
in Bone and Mineral Metabolism.
Realizing the potential importance of
newly discovered growth factors and
cytokines in skeletal homeostasis, Greg
established that transforming growth
factor b is abundant in bone matrix and
chemotactic to osteoblasts. He also de-
termined the potential importance of
parathyroid hormone-related protein in
the pathogenesis of breast cancer-
induced osteolysis. These experiments
provided an important rationale for his
viscous cycle of bone metastasis hypoth-
esis, and proved fundamental to under-
standing the coupling of osteoblast and
osteoclast function that characterizes
skeletal remodeling. Greg also provided
insights into the relationship of newly
discovered inflammatory cytokines such
as tumor necrosis factor and interleukin-
1 to osteoclast function in hypercalcemia
of malignancy. Within the last decade,
Greg established a potential role for sta-
tins and proteosome inhibitors as anabolic
agents in the treatment of osteoporosis.
A masterful writer, Greg published in
excess of 500 scientific papers.m 11, May 5, 2010 ª2010 Elsevier Inc. 347
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ObituaryMore than any other member of our
discipline, Greg Mundy was the paradig-
matic physician-scientist. While focusing
on understanding the fundamental mech-
anisms of bone cell biology, his ultimate
goal was improved patient care. His
translational commitment resulted in the
awarding of 34 patents and the founding
of 2 biotechnology companies and key
participation in 2 others.
Greg’s stature and dedication to our
community is reflected in the many awards
and leadership positions he held. He
served as president of our foremost socie-
ties including the American Society for
Bone and Mineral Research and the Inter-348 Cell Metabolism 11, May 5, 2010 ª2010national Bone and Mineral Society. He
served on the editorial board of many
journals, including Cell Metabolism. He
was an NIH MERIT awardee, and for more
than 20 years, principal investigator of
a program project grant focusing on cancer
and bone that remained funded until his
death.
Greg died as he lived. He refused to
surrender and, until terminal, participated
in experimental design and laboratory
meetings via computer video link from
his home. I spoke to him often during
his last days. He laughed and reflected
on his many good times with family and
friends. He abjured self-pity, and hisElsevier Inc.concern was always the welfare of others,
particularly the team of young investiga-
tors he recruited to build the Bone
Center at Vanderbilt. While it is a cliche´
to claim someone irreplaceable, Greg
Mundy is.
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